2025 LCRF Team Science Award on Advancing Therapies Toward CURING EGFR Mutated Lung Cancers
This award supports collaborative, multidisciplinary projects aimed at developing novel, curative therapies for EGFR-mutant non-small cell lung cancer (NSCLC), with emphasis on understanding and overcoming resistance mechanisms, innovating treatment combinations, and addressing metastatic challenges.
Eligibility Criteria
-
Multi-investigator teams (academia, clinical, industry)
-
Focus on EGFR-mutant NSCLC
-
Projects addressing any of: resistance mechanisms; novel agents (immunotherapy, cell therapy, ADCs, etc.); treatment sequencing; oligometastatic or CNS disease; biomarker-driven strategies
Funding Details
-
Up to 1,500,000 USD total budget
-
Funding period: 3 years
-
Single application per investigator per cycle
Key Deadlines
-
LOI Due: July 29, 2025
-
Full Proposal Invited: (after LOI review)
-
Full Proposal Due: November 4, 2025
-
Award Notifications: (not specified; see RFP)
Where to Apply & More Information
-
Submit LOI via Grant Application Portal
-
See full RFP for detailed instructions at LCRF’s website or contact [email protected]
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023